Identity
- Security key
- 11923
- Ticker
- ARVN
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2018-09-27
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- ARVN
Detail
Enriched 2026-08-14 20:47
- Market cap
- $579,975,514.17
- Shares outstanding (class)
- 64,521,198
- Shares outstanding (weighted)
- 65,386,191
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 246
- Location
- NEW HAVEN, CT
- Homepage
- https://www.arvinas.com
- Description
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.